USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
THERAPYX, INC.
Address:
138 FARBER HALL
3435 MAIN STREET
BUFFALO, NY 14214
Phone:
N/A
URL:
N/A
EIN:
116161309
DUNS:
145056607
Number of Employees:
6
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,068,479.00 6
SBIR Phase II $5,555,128.00 2

Award List:

TUMOR VACCINE:COVALENT LINK OF ANTIGEN TO DENDRITIC CELL

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$158,517.00
Agency:
HHS
Principal Investigator:
Qiang Lou
Abstract:
DESCRIPTION (provided by applicant): The ability of dendritic cells (DC) to activate naive T-cells has made them targets for the design of enhanced vaccination protocols. DC loaded with tumor antigens in vitro and injected into recipients, have induced protective immune responses in several… More

TUMOR IMMUNOTHERAPY WITH BIODEGRADABLE MICROSPHERES

Award Year / Program / Phase:
2003 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Proof of principle for the feasibility of our proprietary tumor vaccination strategy involving the use of Interleukin-12-encapsulated microspheres has been demonstrated in Phase I studies. A single intra-tumoral injection of Interleukin-12-encapsulated… More

TUMOR IMMUNOTHERAPY WITH BIODEGRADABLE MICROSPHERES

Award Year / Program / Phase:
2003 / SBIR / Phase II
Award Amount:
$2,555,134.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Proof of principle for the feasibility of our proprietary tumor vaccination strategy involving the use of Interleukin-12-encapsulated microspheres has been demonstrated in Phase I studies. A single intra-tumoral injection of Interleukin-12-encapsulated… More

Treatment of Type 2 Diabetes with Oral Administration of Nanoencapsulated GLP-1

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$144,961.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Type 2 diabetes mellitus is one of the leading causes of death and disability in the world. While current treatments prevent some of diabetes' more damaging complications, they can neither restore normoglycemia nor eliminate all the harmful effects caused by long… More

Co-encapsulation of IroN and IL-12 as an Extra-intestinal E. coli Vaccine.

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$292,501.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Despite recent advances in the treatment and prevention of infectious disease, the threat to world health continues to grow. The spread of new zoonotic viral strains like avian influenza and the emergence of antibiotic resistant forms of long established… More

Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$172,500.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The disorders collectively known as inflammatory bowel disease (IBD) include Crohn's disease (CD) and ulcerative colitis (UC) and affect up to one million people in the US. Both UC and CD result from uncontrolled chroni c inflammatory activity in the GI tract.… More

Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$2,999,994.00
Agency:
HHS
Principal Investigator:
Thomas F. Conway – 716-829-2528
Abstract:
DESCRIPTION (provided by applicant): Phase I studies established proof-of-principle for the efficacy of oral sustained-release TGF?1 (TPX-6001) and ATRA (TPX-7001) nanoparticles in the treatment of IBD in a murine adoptive T-cell transfer model. Specifically, a two-week regimen of oral TPX-6001 and… More

A novel, multiparametric cardiac safety assay using human myocytes

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Yingru Liu – 716-829-2528
Abstract:
DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency; there is no vaccine… More